Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
A Fibroblast Growth Factor Antagonist Peptide Inhibits Breast Cancer in Balb/C Mice Publisher



Jafarzadeh M1 ; Mousavizadeh K2, 3 ; Joghataei MT2, 4 ; Bahremani MH5 ; Safa M6 ; Asghari SM7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Biology, University Campus2, University of Guilan, Rasht, Iran
  2. 2. Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Neuroscience, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Pathology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  6. 6. Department of Hematology, School of Allied Medical Science, Iran University of Medical Sciences, Tehran, Iran
  7. 7. Department of Biology, Faculty of Sciences, University of Guilan, Rasht, Iran

Source: Open Life Sciences Published:2018


Abstract

Given the role of basic fibroblastic growth factor (bFGF) in tumor growth, it has been considered as a potential target for tumor therapy. In this study, we investigate the effect of bFGF antagonistic peptide on the growth and angiogenesis of 4T1 mammary carcinoma tumor (MCT) in BALB/c mice. An engineered peptide was injected into BALB/c mice in doses of 1, 2.5, 5 and 10 mg/kg daily for 14 days. Immunohistochemical analysis using anti-CD31 and anti-CD34 were conducted as indices of angiogenesis. In addition, blood samples were taken from the eyes of treated and control mice and the levels of Interleukin-8 (IL-8) and Tumor Necrosis Factor-α (TNF-α) were measured by ELISA. Data was analyzed by ANOVA using SPSS. The antagonistic peptide inhibited growth and angiogenesis of MCT (P ≤0.05), and decreased the serum level of IL-8 and TNF-α in treated groups compared to the control groups. The inhibition of tumor angiogenesis has been considered as an important strategy to halt tumor growth. The results of current study confirm that the antiangiogenic peptide effectively inhibited the growth of MCT, and shows potential for clinical trials for the treatment of cancer in humans. © 2018 Mehrzad Jafarzadeh et al., published by De Gruyter.
Related Docs
1. Tumor-Suppressing and Anti-Angiogenic Activities of a Recombinant Anti-Cd3ϵ Nanobody in Breast Cancer Mice Model, Immunotherapy (2019)
2. Extraction of Vessel Structure in Thermal Images to Help Early Breast Cancer Detection, Computer Methods in Biomechanics and Biomedical Engineering: Imaging and Visualization (2020)